Abstract:Abstract Background :Hemophilia A (HA) is an X-linked monogenic coagulation disorder resulting from deficiency of the factor VIII (FVIII, F8) gene in the intrinsic coagulation cascade. The current treatment of HA is based on protein replacement therapy (PRT) through plasma-derived coagulation factors or recombinant proteins with limitations of short half-life, high cost, and life-time requirement of the treatment. Gene therapy has become a promising treatment for HA. Methods and Materials: We developed an advanced lentiviral vector (LV) system for intravenous (iv) F8 gene therapy. A selective codon optimized and B-domain deleted human F8 (hF8BDD) gene was synthesized, sequenced and functionally verified. LVs carrying a universal EF1α promoter, or several modified tissue-specific promoters including endothelial- (VEC), endothelial and epithelial- (KDR), and two megakaryocyte-specific (ITGA and Gp) promoters, were biologically and immunologically characterized in vitro using human endothelial and megakaryocytic cell lines, EA-hy926 and DAMI, and in vivo using F8 knockout (KO) mice. Results: We investigated the different LV promoter constructs and found that LV-VEC-F8BDD exhibited the highest virus packaging (1.3x10 9 transduction units/ml) and transduction efficiencies compared with the other LV constructs. Tissue-specific expression of the VEC, KDR, ITGA and Gp promoters was confirmed in EA-hy926 and DAMI cells by RT-PCR, Western blot and ELISA analyses. We detected F8 activities close to 6 folds and 4.5 folds above the normal plasma level from the EF1a LV-F8BDD transduced EA-hy926 cells and DAMI cells, respectively, whereas the VEC LV in EA-hy926 cells and the ITGA-LV in DAMI cells exhibited F8 activities at 1.5 folds and 5 folds above the normal plasma level, respectively. In vivo studies in F8 KO mice via iv injection of LVs after reduced radiation conditioning illustrated preferential vector expression in different cell lineages, with high expression of EF1a vector in CD11b, F4/80 and Ly-6G positive immune cells, and preferential expression of VEC vector in CD31 positive endothelial cells, and ITGA and Gp vectors in CD41 positive megakaryocytes. In addition, we detected variable phenotypic corrections as well as anti-F8 immune responses in the F8 KO mice treated with the different LVs. The iv deliveries of VEC and Gp F8BDD vectors illustrated therapeutic F8 activities over time, around 25% and 8%, respectively, in 60 days, which increased to high levels (80% and 25%, respectively) after 120 days (Figure A). Kinetic analyses of anti-F8 IgG and inhibitor titers (Bethesda assay) of the treated mice showed that the VEC vector exhibited the lowest F8 inhibitory immune response over time (Figure B). Conclusion: Based on the in vitro and in vivo studies, our results suggest that for HA gene therapy, optimal rather than high F8 expression is critical, and tissue-specific expression but not universal expression can reduce adverse inhibitor effect. We demonstrated that the LV-VEC-F8BDD vector displayed high tissue specificity in vivo, and high transgene delivery efficiency, high coagulation function and low immunogenicity. In addition, iv LV gene therapy could be a safe, convenient and effective HA gene therapy strategy. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

[Optimized AAV Package and Experimental Application of Recombinant AAV8/hFⅧ for Gene Therapy on Hemophilia A Mice].

Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Enhanced factor VIII heavy chain for gene therapy of hemophilia A.

Adeno-associated Virus-Mediated Expression of Activated Factor V (fva) for Hemophilia Phenotypic Correction

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Evaluation of the Activity Levels of Rat FVIII and Human FVIII Delivered by Adeno-Associated Viral Vectors Both in Vitro and in Vivo.

Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.

[Preliminary Experimental Research on Gene Therapy for Hemophilia A].

High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines

Exploring the potential feasibility of intra-articular adeno-associated virus-mediated gene therapy for hemophilia arthropathy.

[Preparation of Raav2/hfix and Experimentally Application to Gene Therapy for Hemophilia B].

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy

Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice

Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog

Intravenous Lentiviral Gene Therapy for Hemophilia a: In Vitro and In Vivo Assessment of Universal Versus Tissue-Specific Promoters

Efficient Transfer and Expression of Human Clotting Factor IX Cdna in Neonatal Hemophilia B Mice Mediated by VSV-G Pseudotyped Retrovirus

Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A.